En undersøgelse, der evaluerer effektiviteten og sikkerheden af Cevostamab i tidligere B-cellemodningsantigen (BCMA)-eksponerede deltagere med recidiverende/refraktær myelomatose (CAMMA 2)
Et fase I/II, åbent, multikohortstudie til evaluering af effektiviteten og sikkerheden af cevostamab i tidligere antigeneksponerede B-cellemodningspatienter med recidiverende/refraktært myelomatose
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Waratah, New South Wales, Australien, 2298
- Calvary Mater Newcastle
-
-
Victoria
-
Fitzroy, Victoria, Australien, 3065
- St Vincent's Hospital Melbourne
-
-
-
-
-
Leuven, Belgien, 3000
- UZ Leuven Gasthuisberg
-
-
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045-2517
- University of Colorado
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Mayo Clinic-Jacksonville
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland Greenebaum Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic - Rochester
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10029
- Icahn School of Medicine at Mount Sinai (ISMMS)
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Tennessee Oncology - Nashville
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Hunstman Cancer Institute
-
-
-
-
-
Nantes, Frankrig, 44093
- CHU NANTES - Hôtel Dieu
-
Paris, Frankrig, 75475
- APHP - Hospital Saint Louis
-
Poitiers, Frankrig, 86021
- CHU de Poitiers - La Miletrie
-
-
-
-
-
Jerusalem, Israel, 9112001
- Hadassah Ein Karem Hospital
-
Ramat Gan, Israel, 5262100
- Sheba Medical Center
-
Tel Aviv, Israel, 6423906
- Sourasky Medical Centre
-
-
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italien, 40138
- Policlinico S.Orsola-Malpighi
-
-
Lombardy
-
Bergamo, Lombardy, Italien, 24127
- Asst Papa Giovanni Xxiii
-
Milan, Lombardy, Italien, 20133
- Fond. IRCCS Istituto Nazionale Tumori
-
-
Piedmont
-
Turin, Piedmont, Italien, 10126
- A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette
-
-
-
-
-
Barcelona, Spanien, 08036
- Hospital Clínic i Provincial
-
Madrid, Spanien, 28041
- Hospital Univ. 12 de Octubre
-
-
-
-
-
Cologne, Tyskland, 50924
- Klinik der Uni zu Köln
-
Hamburg, Tyskland, 20246
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
-
Würzburg, Tyskland, 97080
- Universitätsklinikum Würzburg
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Documented diagnosis of MM based on standard International Myeloma Working Group (IMWG) criteria
- Evidence of progressive disease based on investigators determination of response by IMWG criteria on or after their last dosing regimen
- Prior BCMA ADC or CAR-T Cohort: participants who have received a BCMA-targeted CAR-T or ADC therapy and are triple-class relapsed or refractory
- Prior BCMA Bispecific Cohort: participants who have received a BCMA-targeting T-cell-dependent bispecific (TDB) antibody and are triple-class relapsed or refractory
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy is at least 12 weeks
- Agreement to protocol-specified assessments, including bone marrow biopsy and aspirate samples as detailed in the protocol
- Resolution of AEs from prior anti-cancer therapy to Grade =< 1
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for at least 5 months after the final dose of cevostamab and for 3 months after the last dose of tocilizumab was administered
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm during the treatment period and for at least 2 months after the final dose of tocilizumab (if applicable) to avoid exposing the embryo
Exclusion Criteria:
- Inability to comply with protocol-mandated hospitalization
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 5 months after the final dose of cevostamab or tocilizumab or within 3 months after the last dose of tocilizumab (if applicable)
- Prior treatment with cevostamab or another agent with the same target
- Prior BCMA ADC or CAR-T Cohort: prior treatment with any T cell dependent bi-specific antibody (TDB) antibody including non BCMA targeting TDB
- Prior use of any monoclonal antibody (mAb), radioimmunoconjugate, or ADC as anti-cancer therapy within 4 weeks before first study treatment, except for the use of non-myeloma therapy
- Prior treatment with systemic immunotherapeutic agents
- Prior treatment with CAR-T cell therapy within 12 weeks before first cevostamab infusion
- Known treatment-related, immune-mediated adverse events associated with prior checkpoint inhibitors
- Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment
- Autologous stem cell transplantation (SCT) within 100 days prior to first study treatment
- Prior allogeneic SCT
- Circulating plasma cell count exceeding 500/ microliter (µL) or 5% of the peripheral blood white cells
- Prior solid organ transplantation
- History of autoimmune disease
- History of confirmed progressive multifocal leukoencephalopathy
- History of severe allergic or anaphylactic reactions to mAb therapy
- Known history of amyloidosis
- Lesions in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
- History of other malignancy within 2 years prior to screening, except those with negligible risk of metastasis or death, such as ductal carcinoma in situ not requiring chemotherapy, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, low-grade, localized prostate cancer not requiring treatment or appropriately treated Stage I uterine cancer
- Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, neurodegenerative disease, or CNS involvement by MM
- Significant cardiovascular disease that may limit a potential participant's ability to adequately respond to a cytokine release syndrome (CRS) event
- Symptomatic active pulmonary disease or requiring supplemental oxygen
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection requiring treatment with IV (intravenous) antimicrobials where the last dose of IV antimicrobial was given within 14 days prior to first study treatment
- Active symptomatic COVID-19 infection at study enrollment or requiring treatment with IV antiviral where the last dose of IV antiviral treatment was given within 14 days prior to first study treatment. Participants with active COVID-19 infection must have clinical recovery and two negative antigen tests at least 24 hours apart prior to first study treatment
- Positive and quantifiable Epstein-Barr virus (EBV) polymerase chain reaction (PCR) or cytomegalovirus (CMV) PCR prior to first study treatment
- Known or suspected chronic active EBV infection
- Known history of Grade >=3 CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) with prior bispecific therapies
- Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
- Recent major surgery within 4 weeks prior to first study treatment
- Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV) infection
- Acute or chronic hepatitis C virus (HCV) infection
- Known history of human immunodeficiency virus (HIV) seropositivity
- Administration of a live, attenuated vaccine within 4 weeks before first study treatment or anticipation that such a live attenuated vaccine will be required during the study
- Treatment with systemic immunosuppressive medications, with the exception of corticosteroid treatment <= 10 mg/day prednisone or equivalent, within 2 weeks prior to first study treatment
- History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
- Any medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cohort A1: Prior BCMA antibody-drug conjugate (ADC) or chimeric antigen receptor T (CAR-T)
Participants in Cohort A1 will be treated at the double step-up split dosing regimen. |
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary. Cevostamab will be administered by IV infusion in 21-day cycles. |
|
Eksperimentel: Cohort A2: Prior BCMA Bispecific
Participants enrolled into exploratory Cohort A2 will receive the same dosing regimen as Cohort A1. |
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary. Cevostamab will be administered by IV infusion in 21-day cycles. |
|
Eksperimentel: Cohort B1: Prior BCMA CAR-T
Participants enrolled in expansion Cohort B1, will be given cevostamab at the selected dosing regimen. |
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary. Cevostamab will be administered by IV infusion in 21-day cycles. |
|
Eksperimentel: Cohort B2: Prior BCMA Bispecific
Expansion Cohort B2 will be opened, after the initial results from Cohort A2, at the same dose as per Cohort B1. |
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary. Cevostamab will be administered by IV infusion in 21-day cycles. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentdel af deltagere med uønskede hændelser
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Objektiv responsrate (ORR) som bestemt af investigator
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal antilægemiddelantistoffer (ADA'er) mod Cevostamab ved baseline
Tidsramme: Baseline
|
Baseline
|
|
Varighed af svar (DOR)
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Rate of Complete Response (CR) eller bedre
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Rate of Very Good Partial Response (VGPR) eller bedre
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Samlet overlevelse (OS)
Tidsramme: Baseline indtil døden uanset årsag (op til ca. 2 år)
|
Baseline indtil døden uanset årsag (op til ca. 2 år)
|
|
Progressionsfri overlevelse (PFS)
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Tid til første svar (for deltagere, der opnår et objektivt svar)
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Tid til bedste respons (for deltagere, der opnår en objektiv respons)
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Procentdel af deltagere, der oplever en klinisk meningsfuld forbedring i træthedsdomænet for den europæiske organisation for forskning og behandling af kræft (EORTC) livskvalitet Core-30 spørgeskema (QLQ-C30) og EORTC QLQ-MY20
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Tid til forringelse af træthedsdomænet for EORTC QLQ-C30 og/eller sygdomssymptomer-domænet for EORTC QLQ-MY20
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Serumkoncentration af Cevostamab på specificerede tidspunkter
Tidsramme: Ved cyklus 1, 2, 3, 4, 6, 8 og hver anden cyklus indtil afslutningen af behandlingen op til ca. 2 år. Hver cyklus er 21 dage.
|
Ved cyklus 1, 2, 3, 4, 6, 8 og hver anden cyklus indtil afslutningen af behandlingen op til ca. 2 år. Hver cyklus er 21 dage.
|
|
Procentdel af deltagere med ADA'er mod Cevostamab under undersøgelsen
Tidsramme: Op til cirka 2 år
|
Op til cirka 2 år
|
|
Cytokinfrigivelsessyndrom (CRS) efter administration af Tocilizumab
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Forholdet mellem serumkoncentration af cevostamab og cytokinfrigivelse
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Forholdet mellem serumkoncentration af Cevostamab og T-cellenummer
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
Forholdet mellem serumkoncentration af Cevostamab og T-celleaktiveringstilstand
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
|
ORR som fastlagt af den uafhængige revisionskomité (IRC)
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Minimal Residual Disease (MRD) negativ rate
Tidsramme: Baseline op til cirka 2 år
|
Baseline op til cirka 2 år
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Hemiske og lymfatiske sygdomme
- Myelomatose
- tocilizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CO43476
- 2021-006816-10 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .